Basilea Pharmaceutica
| Company type | Public |
|---|---|
| SIX: BSLN | |
| Industry | Pharmaceutical industry |
| Founded | 2000 |
| Headquarters | Allschwil, Switzerland |
Key people | David Veitch (Chief Executive Officer) Domenico Scala (Chairman of the Board) |
| Products | Isavuconazole, Ceftobiprole |
| Revenue | CHF 157.6 million (2023) |
Number of employees | 147 (2023) |
| Website | www |
Basilea Pharmaceutica is a biopharmaceutical company based in Allschwil near Basel, Switzerland. Basilea was spun off from F. Hoffmann-La Roche in 2000 and has been listed as an independent company on the Swiss stock exchange since March 2004. The company's subsidiary is Basilea Pharmaceutica International AG, Allschwil, which is also based in Allschwil, Switzerland, and in which the company's operating activities are bundled.